{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:59:31Z","timestamp":1790287171240,"version":"4.1.0"},"reference-count":81,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Anthracyclines are one of the most widely used and effective chemotherapies in oncology, but their most important side effect is the cumulative, dose-related cardiotoxicity leading to congestive heart failure in ~5% of individuals. Methodology and pharmacogenetic studies for predicting which individuals are at high risk and subsequently the development of targeted and individualized cardioprotective plans are beginning to make progress. Here, we review current putative risk genes and variants, the strength of evidence for each genetic association and the interaction between risk genes, in the context of known clinical risk factors and potential novel cardioprotective strategies.<\/jats:p>","DOI":"10.3390\/jcm10184079","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:20:37Z","timestamp":1631190037000},"page":"4079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart Failure"],"prefix":"10.3390","volume":"10","author":[{"given":"Nadine","family":"Norton","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan M.","family":"Weil","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja P.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Layard","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"Advani","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization","volume":"88","author":"Bristow","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2019.03.013","article-title":"Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer\u2014A real-world data-based, nationwide classification analysis","volume":"285","author":"Fogarassy","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database","volume":"7","author":"Kim","year":"2018","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/annonc\/mdg070","article-title":"Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"Limat","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.physiol.010908.163156","article-title":"Sex-based cardiac physiology","volume":"71","author":"Luczak","year":"2009","journal-title":"Annu. Rev. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejheart.2007.12.012","article-title":"Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II","volume":"10","author":"Nieminen","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrd2032","article-title":"Therapeutic implications of the gender-specific aspects of cardiovascular disease","volume":"5","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood-2010-01-263764","article-title":"A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease","volume":"116","author":"Myrehaug","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late Mortality Among 5-Year Survivors of Childhood Cancer: A Summary From the Childhood Cancer Survivor Study","volume":"27","author":"Armstrong","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2001.19.7.1926","article-title":"Congestive heart failure after treatment for Wilms\u2019 tumor: A report from the National Wilms\u2019 Tumor Study group","volume":"19","author":"Green","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mpo.2950210704","article-title":"Increased risk of cardiac dysfunction after anthracyclines in girls","volume":"21","author":"Silber","year":"1993","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1249\/MSS.0000000000001395","article-title":"Exercise Protects Skeletal Muscle during Chronic Doxorubicin Administration","volume":"49","author":"Dickinson","year":"2017","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-016-0124-4","article-title":"Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl\/6 mice","volume":"8","author":"Grant","year":"2017","journal-title":"Biol. Sex Differ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.114.001180","article-title":"Sexual dimorphism of doxorubicin-mediated cardiotoxicity: Potential role of energy metabolism remodeling","volume":"8","author":"Moulin","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_26","first-page":"4","article-title":"The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity","volume":"2","author":"Zordoky","year":"2016","journal-title":"Cardiooncology"},{"key":"ref_27","first-page":"154","article-title":"Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations","volume":"5","author":"Singh","year":"2020","journal-title":"Int. J. Clin. Res. Trials"},{"key":"ref_28","first-page":"196","article-title":"Doxorubicin cardiotoxicity in African Americans","volume":"96","author":"Hasan","year":"2004","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/pbc.24498","article-title":"Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A North American perspective","volume":"60","author":"Orgel","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jjcc.2019.02.001","article-title":"Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: A 10-year multicenter cohort study","volume":"74","author":"Kim","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11764-014-0408-9","article-title":"Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin","volume":"9","author":"Qin","year":"2015","journal-title":"J. Cancer Surviv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1556\/650.2020.31739","article-title":"Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases","volume":"161","author":"Fogarassy","year":"2020","journal-title":"Orvosi Hetil."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.104.002006","article-title":"Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)","volume":"33","author":"Lakhman","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.109.160614","article-title":"Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism","volume":"332","author":"Bains","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes\u2014A report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pgs.15.162","article-title":"Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines","volume":"17","author":"Hertz","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","article-title":"Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"10","author":"Serie","year":"2017","journal-title":"Pharm. Genom."},{"key":"ref_40","first-page":"17","article-title":"CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin","volume":"7","author":"Lang","year":"2021","journal-title":"Cardiooncology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs.14.179","article-title":"Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma","volume":"16","author":"Reichwagen","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-16-0908","article-title":"Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure","volume":"23","author":"Schneider","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FPC.0000000000000284","article-title":"Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults","volume":"27","author":"Wells","year":"2017","journal-title":"Pharm. Genom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","article-title":"CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children\u2019s Oncology Group Genome-Wide Association Study","volume":"34","author":"Wang","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fcvm.2020.00142","article-title":"Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure","volume":"7","author":"Norton","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41586-019-1310-4","article-title":"Genetic analyses of diverse populations improves discovery for complex traits","volume":"570","author":"Wojcik","year":"2019","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: The complexity of a diverse genetic architecture","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-015-3437-9","article-title":"Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients","volume":"152","author":"Vulsteke","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153ps18","DOI":"10.1126\/scitranslmed.3003471","article-title":"Pharmacogenomics and patient care: One size does not fit all","volume":"4","author":"Giacomini","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000494391","article-title":"Cubilin Single Nucleotide Polymorphism Variants are Associated with Macroangiopathy While a Matrix Metalloproteinase-9 Single Nucleotide Polymorphism Flip-Flop may Indicate Susceptibility of Diabetic Nephropathy in Type-2 Diabetic Patients","volume":"141","author":"Albert","year":"2019","journal-title":"Nephron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/512133","article-title":"No gene is an island: The flip-flop phenomenon","volume":"80","author":"Lin","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4238\/2014.January.8.1","article-title":"Gender flip-flop association between genetic variations of NEDD4L and metabolic syndrome in the Kazakh general population","volume":"13","author":"Wang","year":"2014","journal-title":"Genet. Mol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/hmg\/ddz018","article-title":"A study in scarlet: MC1R as the main predictor of red hair and exemplar of the flip-flop effect","volume":"28","author":"Lichtenwalter","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.celrep.2014.07.024","article-title":"A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance","volume":"8","author":"Khurana","year":"2014","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncomms1601","article-title":"BRCA1 is an essential regulator of heart function and survival following myocardial infarction","volume":"2","author":"Shukla","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"1000 Genomes Project Consortium, Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin, R.M., Hurles, M.E., and McVean, G.A. (2010). A map of human genome variation from population-scale sequencing. Nature, 467, 1061\u20131073.","DOI":"10.1038\/nature09534"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/MCB.21.4.1285-1296.2001","article-title":"The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing","volume":"21","author":"Ladd","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_65","unstructured":"Norton, N., Necela, B.M., Wang, X.L., Lu, T., and Lee, H.C. (2021, July 20). TRPC6 Gain-of-Function in Doxorubicin-Induced Heart Failure. Available online: https:\/\/eventpilotadmin.com\/web\/planner.php?id=ASHG21."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1253\/circj.CJ-13-0154","article-title":"Characteristics of transient receptor potential canonical calcium-permeable channels and their relevance to vascular physiology and disease","volume":"77","author":"Beech","year":"2013","journal-title":"Circ. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1172\/JCI27702","article-title":"TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling","volume":"116","author":"Kuwahara","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10156","DOI":"10.1073\/pnas.1815354116","article-title":"In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease","volume":"116","author":"Lin","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10637-017-0443-2","article-title":"Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents","volume":"35","author":"Piska","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Simunek","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e12993","DOI":"10.1111\/acel.12993","article-title":"Peroxisome proliferator-activated receptor gamma coactivator 1alpha regulates mitochondrial calcium homeostasis, sarcoplasmic reticulum stress, and cell death to mitigate skeletal muscle aging","volume":"18","author":"Gill","year":"2019","journal-title":"Aging Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/j.bbadis.2018.08.007","article-title":"Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases","volume":"1864","author":"Kim","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/jpet.113.206805","article-title":"A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin","volume":"347","author":"Bains","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/01.RES.0000194329.41863.89","article-title":"Ca2+\/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure","volume":"97","author":"Ai","year":"2005","journal-title":"Circ. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00424-021-02533-2","article-title":"Stress-driven cardiac calcium mishandling via a kinase-to-kinase crosstalk","volume":"473","author":"McKee","year":"2021","journal-title":"Pfl\u00fcg. Arch."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCRESAHA.112.268094","article-title":"Role of RyR2 Phosphorylation at S2814 During Heart Failure Progression","volume":"110","author":"Respress","year":"2012","journal-title":"Circ. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCEP.107.754788","article-title":"Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure","volume":"1","author":"Yeh","year":"2008","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrc.2017.18","article-title":"The calcium-cancer signalling nexus","volume":"17","author":"Monteith","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"581455","DOI":"10.3389\/fphar.2020.581455","article-title":"TRP Channels and Small GTPases Interplay in the Main Hallmarks of Metastatic Cancer","volume":"11","author":"Chinigo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Jardin, I., Diez-Bello, R., Lopez, J.J., Redondo, P.C., Salido, G.M., Smani, T., and Rosado, J.A. (2018). TRPC6 Channels Are Required for Proliferation, Migration and Invasion of Breast Cancer Cell Lines by Modulation of Orai1 and Orai3 Surface Exposure. Cancers, 10.","DOI":"10.3390\/cancers10090331"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:59:36Z","timestamp":1760165976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":81,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10184079"],"URL":"https:\/\/doi.org\/10.3390\/jcm10184079","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}